Emilio Mohanna ISEE.720 Consider how the company designed its production system during the early stages of the pandemic and how Moderna's challenges have evolved in the last two years. See yourself as a technical consultant hired by Moderna to support the production of its novel vaccine candidate. -- What actions taken by Moderna to scale up its production would you have also taken? -- What suggestions would you have made to Moderna (at the beginning of the pandemic) given the information you know now about the pandemic? -- --- --- Please consider design for manufacturing, sustainability, and logistics in answering these questions? The story of Moderna is very nice. It is essentially a biotech research company that tackled what most companies even outside of pharma and biotech struggle with: Managing data using artificial intelligence whilst getting rid of data silos Getting rid of human error Automation Internet of things and implementing cross-department sharing of info Outsourcing vs in-house And many other challenges. The reason Moderna was so proficient at creating the genetic sequence, finding a way to deliver those sequences (method of containing i.e. carrying oil) and creating the vaccine required for all 3 phases of clinical trial was due to the fact that the infrastructure was there from the start, the company was already digitized, automated, had the mRNA platform ready (they only have to figure out which proteins to use) so when the Chinese govt. released the DNA sequence for the coronavirus, it only took 42 days to build the suitable vaccine, all by computer of course. They also had taken the risk of building a manufacturing and research facility costing 125 million dollars just one hour away from HQ to facilitate the logistics of any endeavour. As a consultant for Moderna, I couldn’t have agreed more to the collaboration effort with the Swiss biotech company, Lonza. The logistical, manufacturing and supply chain challenges of accommodating the whole world with vaccines is impossible for Moderna to do alone. Now they can have an aid in the production in addition to a new front in the continent of Europe. The suggestions I would have made to Moderna knowing what I know now: Many countries other than the USA have had one or maybe 2 vaccines that were provided by the govt. many of which were not Moderna. This could be due to the insufficient capacity for Emilio Mohanna ISEE.720 Moderna to supply these countries. Or logistical challenges associated with the distance. That is essentially opportunity cost on Moderna, a market that Moderna could have sold to. Moderna had 2 large grants, and even though the article does not mention what these grants were used for, a suggestion would have been to either build manufacturing cells all around the globe and have them all inter-connected. Or collaborate with local bio-manufacturers in different regions and use the grant money to set up the needed infrastructure, digitization and automation to match with Moderna’s processes. To ensure sustainability, looking for a supplier who can provide recyclable syringes would be key, disposing billions of syringes is neither economical, sustainable, or environmentally responsible.